抑制脂肪酸酰胺水解酶改善神经病理性疼痛大鼠抑郁样行为且不依赖外周镇痛效应
该研究在慢性坐骨神经缩窄损伤(CCI)大鼠模型中发现,全身性脂肪酸酰胺水解酶(FAAH)抑制剂URB597和外周性FAAH抑制剂URB937均能提高机械痛阈,但仅URB597改善抑郁样行为并促进海马神经发生,提示FAAH抑制改善神经病理性疼痛诱导的抑郁不依赖其外周镇痛作用。
要点
- 全身性FAAH抑制剂URB597改善CCI大鼠抑郁样行为并促进海马神经发生。
- 外周性FAAH抑制剂URB937镇痛但不改善抑郁样行为,提示中枢机制参与。
- FAAH抑制的抗抑郁效应可能独立于外周镇痛作用。
核心结论
- 抑制FAAH可改善神经病理性疼痛诱导的抑郁样行为,且独立于其外周镇痛作用。
- 海马神经发生增强可能参与URB597的抗抑郁效应。
研究设计与样本
- 成年雄性Wistar大鼠行坐骨神经慢性缩窄损伤(CCI)建立神经病理性疼痛模型。
- 术后第15天起分别腹腔注射URB597(5.8 mg·kg·day)或URB937(1.6 mg·kg·d),持续15天,每组n=11–12。
- 采用Von Frey测试机械缩足阈值,强迫游泳实验(FST)和新奇摄食抑制(NSF)评估抑郁样行为,液质联用检测海马内源性大麻素水平,免疫组化评估海马神经发生。
主要发现
- CCI大鼠出现持续机械痛敏,FST不动时间显著延长(假手术组84.2 ± 13.4秒 vs CCI组137.9 ± 18.8秒,P < .001),NSF摄食潜伏期延长(假手术组133.4 ± 19.4秒 vs CCI组234.9 ± 33.5秒,P < .001)。
- 与溶媒对照组相比,URB597(3.1 ± 1.0 vs 11.2 ± 1.2 g,P < .001)和URB937(3.1 ± 1.0 vs 12.1 ± 1.3 g,P < .001)均提高痛阈。
- URB597降低FST不动时间(135.8 ± 16.6 vs 85.3 ± 17.2秒,P < .001)和NSF摄食潜伏期(235.9 ± 30.5 vs 131.8 ± 19.8秒,P < .001),URB937无此效应(FST:135.8 ± 16.6 vs 129.6 ± 17.8秒,P = .78;NSF:235.9 ± 30.5 vs 232.2 ± 33.2秒,P = .72)。
- CCI减少海马增殖细胞数量并降低新生成熟神经元存活,URB597而非URB937改善这些细胞缺陷。
临床怎么用
- 动物实验提示FAAH抑制剂的中枢作用可能同时改善神经病理性疼痛相关抑郁,但尚未转化为临床推荐。
- 外周限制性FAAH抑制剂虽有镇痛作用但不改善抑郁,提示若用于疼痛共病抑郁需关注中枢靶点。
局限性
- 仅使用雄性大鼠,结论不能直接外推至雌性。
- 动物模型结果需进一步临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neuropathic pain is often associated with depression. Enhancing endocannabinoids by fatty acid amide hydrolase (FAAH) inhibitors relieves neuropathic pain and stress-induced depressive-like behaviors in animal models. However, it is unclear whether FAAH inhibitor can relieve neuropathic pain-induced depression by or not by its antinociceptive effects. METHODS: Adult male Wistar rats with chronic constriction injury (CCI) to the sciatic nerve were treated with the systemic FAAH inhibitor URB597 (5.8 mg·kg·day, intraperitoneally) or peripherally acting FAAH inhibitor URB937 (1.6 mg·kg·d, intraperitoneally; n = 11-12). The treatment was applied from the 15th day after surgery and continued for 15 days. Mechanical withdrawal threshold was examined by Von Frey test before surgery and on the 28th day after CCI. Depressive-like behaviors were evaluated by forced swimming test (FST) and novelty-suppressed feeding (NSF) after 15-day treatment. The levels of anandamide and 2-arachidonoylglycerol in hippocampus were examined by liquid chromatography and mass spectrometry. Hippocampal neurogenesis including proliferation, differentiation, and survival of newborn cells was assessed by immunohistochemistry. RESULTS: After CCI injury, the rats developed significantly nociceptive and depressive-like behaviors, indicated by persistent mechanical hypersensitivity in Von Frey test, significantly prolonged immobility time in FST (sham: 84.2 ± 13.4 seconds versus CCI: 137.9 ± 18.8 seconds; P < .001), and protracted latency to feed in NSF (sham: 133.4 ± 19.4 seconds versus CCI: 234.9 ± 33.5 seconds; P < .001). For the CCI rats receiving treatment, compared to vehicle placebo group, pain threshold was increased by both URB597 (3.1 ± 1.0 vs 11.2 ± 1.2 g; P < .001) and URB937 (3.1 ± 1.0 vs 12.1 ± 1.3 g; P < .001). Immobility time of FST was reduced by URB597 (135.8 ± 16.6 vs 85.3 ± 17.2 seconds; P < .001) but not by URB937 (135.8 ± 16.6 vs 129.6 ± 17.8 seconds; P = .78). Latency to feed in NSF was also reduced by URB597 (235.9 ± 30.5 vs 131.8 ± 19.8 seconds; P < .001) but not by URB937 (235.9 ± 30.5 vs 232.2 ± 33.2 seconds; P = .72). Meanwhile, CCI decreased the number of proliferating cells and reduced survival of new mature neurons in hippocampus. URB597 but not URB937 treatment improved these cellular deficits. CONCLUSIONS: Inhibition of FAAH can improve depressive-like behaviors induced by neuropathic pain independent of its peripheral antinociceptive action. Enhanced neurogenesis in hippocampus might contribute to the antidepressive effects of URB597.
引用
- Jiang HX, Ke BW, Liu J, et al. Inhibition of Fatty Acid Amide Hydrolase Improves Depressive-Like Behaviors Independent of Its Peripheral Antinociceptive Effects in a Rat Model of Neuropathic Pain. Anesth Analg. 2019. PMID: 29863609. doi:10.1213/ANE.0000000000003563
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。